Amgen EPO Patent Win Over Roche Could Derail Mircera Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.